前列腺癌雄激素剥夺治疗与神经认知障碍:系统综述与Meta分析
该系统综述与Meta分析检索PubMed、EMBASE、Scopus和Google Scholar至2023年4月,纳入28项研究、共2,543,483例患者,评估雄激素剥夺治疗(ADT)与痴呆、阿尔茨海默病、血管性痴呆、抑郁及帕金森病的关联。结果显示ADT显著增加痴呆、阿尔茨海默病、抑郁和帕金森病风险,血管性痴呆风险未达统计学显著。
要点
- ADT与抑郁(HR 1.66)和帕金森病(HR 1.57)风险升高相关。
核心结论
- 基于现有证据分析,ADT显著增加痴呆、阿尔茨海默病、帕金森病和抑郁的风险。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、EMBASE、Scopus和Google Scholar从建库至2023年4月发表的文献。
- 初检识别305项研究,最终纳入28项符合纳入标准的研究。
- 27项研究报告了患者数,共2,543,483例,其中接受ADT的前列腺癌患者900,994例,未接受ADT的前列腺癌患者1,262,905例,未患前列腺癌且未接受ADT者334,682例。
关键数值与推荐
- 异质性采用Higgins I²评估,I²超过50%视为异质性,采用随机效应模型分析;否则采用固定效应模型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer is a prevalent disease that urgently needs to address its treatment-related complications. By examining existing evidence on the association between Androgen Deprivation Therapy (ADT) and dementia, this study contributes to the understanding of potential risks. We sought to analyze the currently available evidence regarding the risk of dementia, Alzheimer's disease (AD), vascular dementia, and Parkinson's disease (PD) in patients undergoing ADT. METHODS: A systematic search of PubMed, EMBASE, Scopus, and Google Scholar was performed to identify studies published from the databases' inception to April 2023. Studies were identified through systematic review to facilitate comparisons between studies with and without some degree of controls for biases affecting distinctions between ADT receivers and non-ADT receivers. This review identified 305 studies, with 28 meeting the inclusion criteria. Heterogeneity was assessed using Higgins I2%. Variables with an I2 over 50% were considered heterogeneous and analyzed using a Random-Effects model. Otherwise, a Fixed-Effects model was employed. RESULTS: A total of 28 studies were included for analysis. Out of these, only 1 study did not report the number of patients. From the remaining 27 studies, there were a total of 2,543,483 patients, including 900,994 with prostate cancer who received ADT, 1,262,905 with prostate cancer who did not receive ADT, and 334,682 patients without prostate cancer who did not receive ADT. This analysis revealed significantly increased Hazard Ratios (HR) of 1.20 [1.11, 1.29], p < 0.00001 for dementia, HR 1.26 [1.10, 1.43], p = 0.0007 for Alzheimer's Disease, HR 1.66 [1.40, 1.97], p < 0.00001 for depression, and HR 1.57 [1.31, 1.88], p < 0.00001 for Parkinson's Disease. The risk of vascular dementia was HR 1.30 [0.97, 1.73], p < 0.00001. CONCLUSION: Based on the analysis of the currently available evidence, it suggests that ADT significantly increases the risk of dementia, AD, PD, and depression.
引用
- Hinojosa-Gonzalez DE, Zafar A, Saffati G, et al. Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024. PMID: 38167924. doi:10.1038/s41391-023-00785-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。